The Galaxolide ban is coming.Here’s what indie brands need to know before their next fragrance order.

Keywords: Galaxolide cosmetics EU ban 2026  ·  Galaxolide CMR 1B fragrance restriction  ·  synthetic musk cosmetics regulation Europe  ·  fragrance ingredient ban EU cosmetics

If your products contain a fragrance — purchased from a supplier as a finished blend, an essential oil, or a fragrance compound — there is a specific ingredient you need to check for before your next order. That ingredient is Galaxolide.

In March 2026, ECHA’s Committee for Risk Assessment published its opinion on Galaxolide (HHCB; CAS No. 1222-05-5), concluding that it should be classified as Repr. 1B (H360D) — toxic to reproduction, specifically for effects on the unborn child. That classification, once formally adopted under the CLP Regulation, will trigger a prohibition on its use in cosmetic products under Article 15 of the EU Cosmetics Regulation (EC) No 1223/2009.

Galaxolide is one of the most widely used synthetic musks in commercial fragrance. It is present in perfumes, body lotions, shampoos, shower gels, deodorants, fabric softeners, and a significant proportion of personal care products with a fragrance note. If your supplier’s fragrance blend contains it — and many do — this is a change that will affect your formulations.

What Galaxolide is and why it is used

Galaxolide is a polycyclic musk — a synthetic fragrance ingredient valued for its clean, musky, slightly woody scent and, critically, for its fixative properties. Fixatives slow the evaporation of other fragrance components, extending the longevity of a fragrance on skin. That functional role makes Galaxolide particularly useful in leave-on products where scent persistence matters: body lotions, deodorants, hair care.

It is also highly cost-effective and stable across a wide range of pH levels and temperatures, which explains its prevalence across both premium and mass-market fragrance applications. Galaxolide has been an industry standard ingredient for decades. Its regulatory trajectory is now changing that position.

The regulatory mechanism: from CMR classification to cosmetics ban

Understanding why a RAC opinion in March 2026 leads to a cosmetics restriction requires understanding how the EU’s regulatory pipeline works in practice.

The process begins with a classification under the CLP Regulation (Regulation (EC) No 1272/2008). When ECHA’s RAC concludes that a substance should be classified as CMR — carcinogenic, mutagenic, or toxic to reproduction — that opinion feeds into a formal Commission proposal. Once adopted in Annex VI to CLP, the classification becomes binding.

Article 15 of the EU Cosmetics Regulation then operates automatically: substances classified as CMR 1A or 1B are prohibited in cosmetic products. The only way to remain permitted is through an exemption under Article 15(2), which requires an industry dossier demonstrating safe use at defined concentrations, followed by a positive SCCS opinion.

Galaxolide faces a specific structural obstacle to that exemption pathway. The current conditions of Article 15 require the SCCS to assess safety against food safety criteria — a threshold that polycyclic musks like Galaxolide, with known environmental persistence and bioaccumulation properties, struggle to meet. Without a positive SCCS opinion, no exemption is possible, and the ban follows automatically from the classification.

A potential window exists if the long-anticipated recast of the EU Cosmetics Regulation removes those food safety criteria for SCCS review. But the recast has been delayed repeatedly and no confirmed timeline exists for its adoption. Brands should not plan their formulations around a legislative outcome that remains uncertain.

What this means for indie brands in practice

The immediate practical implication is straightforward: if your fragrance supplier’s blends contain Galaxolide, those blends will need to be reformulated before the restriction applies. The relevant questions to ask now are:

•       Does my current fragrance blend contain Galaxolide (HHCB; CAS No. 1222-05-5)?

•       At what concentration is it present in the blend, and what is the resulting concentration in my finished product?

•       Does my supplier have an alternative blend without Galaxolide, or will reformulation be required from scratch?

•       What is the lead time for a reformulated fragrance, and how does that interact with my production schedule?

The answers to these questions determine how urgent the action is. A brand with three products that use a single supplier fragrance blend has a manageable problem. A brand with fifteen products across multiple suppliers and fragrance houses has a complex reformulation project that requires planning well before the restriction date.

The timeline: what is confirmed and what is not

It is important to be precise about what is known and what remains pending.

What is confirmed: ECHA’s RAC published its opinion recommending a Repr. 1B classification for Galaxolide in March 2026. That opinion is the scientific foundation for a future CLP classification.

What is pending: The formal adoption of the classification in Annex VI to the CLP Regulation has not yet been published in the Official Journal. Once published, the Commission has 15 months to adopt regulatory measures under the Cosmetics Regulation. The effective date of any restriction depends on when the CLP classification is formally adopted.

The practical implication: Brands should not wait for the Official Journal publication to begin supplier conversations. Reformulating a fragrance blend takes time — typically several months from initial brief to finished product with stability data. If the classification is adopted later in 2026, the 15-month window moves quickly. Starting the supplier dialogue now is the difference between a managed transition and a reactive reformulation under time pressure.

Galaxolide is not an isolated case

Galaxolide sits within a broader pattern of fragrance ingredients facing CMR classification pressure. Heliotropin (piperonal) is going through the same process: the SCCS published its preliminary opinion in April 2026, finding it safe only at up to 1.8% in fine fragrances for adults following its proposed Repr. 1B classification under ATP 24. The public consultation closed on 15 June 2026 — the sector is now awaiting the final SCCS opinion, which will determine whether Heliotropin remains permitted in fine fragrances at restricted concentrations or faces a broader prohibition. Hydroxycitronellal has been proposed for classification by the Netherlands. The broader PFAS restriction, while primarily targeting different chemical families, reflects the same regulatory direction: systematic review of persistent and potentially hazardous ingredients across product categories.

The regulatory environment for synthetic fragrance ingredients is tightening. That is not a prediction — it is a description of the current direction of the EU’s Chemicals Strategy for Sustainability, which explicitly targets the substitution of substances of concern in consumer products.

For indie brands, the practical response is not to abandon fragrance. It is to build a supplier relationship that gives you visibility into the composition of your fragrance blends, so that regulatory changes — when they arrive — can be identified and managed before they become a production crisis.

The three things to do before your next fragrance order

1. Request a full composition declaration from your fragrance supplier. Ask specifically whether your current blends contain Galaxolide (HHCB; CAS No. 1222-05-5) and at what concentration. This is a reasonable request — suppliers in well-regulated markets are accustomed to providing this information. If a supplier is unwilling to confirm ingredient composition at this level of detail, that is itself relevant information about your supply chain risk.

2. Assess the reformulation scope. If Galaxolide is present, understand whether your supplier offers an existing alternative blend or whether a new development brief is required. Factor in stability testing, sensory evaluation, and any label changes. Update your Product Information File to document the composition change and ensure your CPSR assessor is informed of the modification.

3. Monitor the CLP classification timeline. The formal adoption of the Repr. 1B classification in Annex VI to CLP will trigger the 15-month countdown. Sign up for ECHA regulatory alerts or follow sources that track CLP Annex VI publications. The gap between RAC opinion and formal adoption can range from several months to over a year — but the process has begun.

At Cláritas Regulatory, we help indie brands assess their fragrance supply chain risk in the context of evolving EU ingredient restrictions — from composition audits to reformulation planning and PIF updates. If you’d like to understand how the Galaxolide regulatory trajectory affects your specific product portfolio, get in touch.